PubRank

J Chataway

Author PubWeight™ 19.85‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat Genet 1996 3.00
2 Testing for urinary tract colonization before high-dose corticosteroid treatment in acute multiple sclerosis relapses: prospective algorithm validation. Eur J Neurol 2012 1.47
3 Global health public-private partnerships: IAVI, partnerships and capacity building. Afr J Med Med Sci 2007 1.22
4 Exploring the dense mapping of a region of potential linkage in complex disease: an example in multiple sclerosis. Genet Epidemiol 1999 1.13
5 Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: an application in multiple sclerosis. Stat Med 2011 0.99
6 Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis. Mult Scler 2008 0.97
7 Offspring recurrence rates and clinical characteristics of conjugal multiple sclerosis. Lancet 1997 0.90
8 Thiamine in Wernicke's syndrome--how much and how long? Postgrad Med J 1995 0.87
9 HLA typing in the United Kingdom multiple sclerosis genome screen. Neurogenetics 1998 0.87
10 A longitudinal study of MRI-detected atrophy in secondary progressive multiple sclerosis. J Neurol 2010 0.86
11 Longitudinal changes in magnetisation transfer ratio in secondary progressive multiple sclerosis: data from a randomised placebo controlled trial of lamotrigine. J Neurol 2011 0.82
12 South Asian strokes: lessons from the St Mary's stroke database. QJM 2009 0.81
13 Grey matter magnetization transfer ratio independently correlates with neurological deficit in secondary progressive multiple sclerosis. J Neurol 2009 0.80
14 Stenosis and carotid endarterectomy. Lancet 2003 0.78
15 It is better to be in a clinical trial than not: lessons learnt from clinical neurology--the management of acute multiple sclerosis relapses. QJM 2012 0.78
16 Clinical and imaging correlates of the multiple sclerosis impact scale in secondary progressive multiple sclerosis. J Neurol 2011 0.77
17 Susceptibility to multiple sclerosis and the immunoglobulin heavy chain gene cluster. Ann Neurol 1998 0.76
18 Thiamine doses for alcohol withdrawal. Br J Hosp Med 1994 0.75
19 No evidence for the involvement of interleukin 2 or the immunoglobulin heavy chain gene cluster in determining genetic susceptibility to multiple sclerosis. J Neurol Neurosurg Psychiatry 2000 0.75
20 General physicians or specialists? J R Coll Physicians Lond 1995 0.75
21 More evidence that founder effects exist in the European population. Eur J Hum Genet 1999 0.75
22 Negotiating the radiologically isolated syndrome. Br J Hosp Med (Lond) 2014 0.75
23 Different white matter lesion characteristics correlate with distinct grey matter abnormalities on magnetic resonance imaging in secondary progressive multiple sclerosis. Mult Scler 2009 0.75
24 Munchausen syndrome by phone. Lancet 2000 0.75
25 FAST-TIA: a prospective evaluation of a nurse-led anterior circulation TIA clinic. Postgrad Med J 2009 0.75